Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study.
Kohei ShitaraYoshitaka HonmaYasushi OmuroKensei YamaguchiKeisho ChinKei MuroShintaro NakagawaSatoe KawakamiShuichi HironakaTomohiro NishinaPublished in: Asia-Pacific journal of clinical oncology (2019)
Efficacy in Japanese patients within GATSBY was consistent with the overall population; overall survival was not prolonged with trastuzumab emtansine 2.4 mg/kg weekly versus taxane. The safety profile of trastuzumab emtansine was similar to the overall population.